Wang Z X, Bhargava A, Sarkar R, Germino F J
Cancer Institute of New Jersey, University of Medicine and Dentistry of NJ, New Brunswick, NJ 08901, USA.
Gene. 1996 Sep 16;173(2):147-54. doi: 10.1016/0378-1119(96)00218-1.
We report the construction of three new vectors which can be used for the 'double-tagging' assay previously reported [Germino et al., Proc. Natl. Acad. Sci. USA 90 (1993) 933-937]. The vectors include two plasmids (pTrc.BCCP and pTrc.EZZ::BCCP) which encode different 'tags' for the capture of a target protein of interest on a filter coated with either avidin or IgG, respectively. The first plasmid (pTrc.BCCP) encodes the C terminus of the biotin carboxylase carrier protein (BCCP) under the control of the Ptac promoter, while the second produces fusions to an IgG-binding domain (EZZ). The gene encoding a protein of interest can be inserted into these plasmids and thereby direct the production of a fusion protein which is biotinylated in vivo and can bind to avidin, or a fusion protein which can bind to IgG. The third is a positive-selection, phase lambda expression vector (lambdaFJG2) which permits the construction of lacZ::cDNA fusion proteins which retain beta-galactosidase activity. The insertion of an active ecoRVR gene between the cloning sites (EcoRI and HindII or NotI) permits the positive selection of inserts. The C-terminal two-thirds of the mouse retinoblastoma-encoding gene (containing the E1A-binding pocket) was cloned into pTrc.BCCP and pTrc.EZZ::BCCP, while the 13S E1a gene was cloned into lambdaFJG2. We show that the interaction between these two proteins can be detected using the 'double-tagging' filter assay, and that this assay has high sensitivity and specificity for detecting this interaction. Finally, we have used these vectors to localize the CDK2-binding domain of the cyclin-dependent kinase inhibitor, p21. These results closely correspond to those obtained using the yeast two-hybrid assay, as well as in vitro binding assays.
我们报道了三种新载体的构建,这些载体可用于先前报道的“双标记”分析[Germino等人,《美国国家科学院院刊》90 (1993) 933 - 937]。这些载体包括两种质粒(pTrc.BCCP和pTrc.EZZ::BCCP),它们分别编码不同的“标签”,用于在涂有抗生物素蛋白或IgG的滤膜上捕获感兴趣的靶蛋白。第一种质粒(pTrc.BCCP)在Ptac启动子的控制下编码生物素羧化酶载体蛋白(BCCP)的C末端,而第二种质粒产生与IgG结合结构域(EZZ)的融合蛋白。编码感兴趣蛋白的基因可插入这些质粒中,从而指导产生在体内生物素化且能与抗生物素蛋白结合的融合蛋白,或能与IgG结合的融合蛋白。第三种是正选择的λ噬菌体表达载体(lambdaFJG2),它允许构建保留β - 半乳糖苷酶活性的lacZ::cDNA融合蛋白。在克隆位点(EcoRI和HindII或NotI)之间插入活性ecoRVR基因可实现对插入片段的正选择。将小鼠视网膜母细胞瘤编码基因的C末端三分之二(包含E1A结合口袋)克隆到pTrc.BCCP和pTrc.EZZ::BCCP中,同时将13S E1a基因克隆到lambdaFJG2中。我们表明,使用“双标记”滤膜分析可检测这两种蛋白之间的相互作用,并且该分析对检测这种相互作用具有高灵敏度和特异性。最后,我们使用这些载体定位了细胞周期蛋白依赖性激酶抑制剂p21的CDK2结合结构域。这些结果与使用酵母双杂交分析以及体外结合分析所获得的结果密切对应。